Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
Nexalin Technology (Nasdaq: NXL) has received USPTO patent approval for its Deep Intracranial Frequency Stimulation (DIFS™) technology, specifically for treating Substance Use Disorders (SUDs). The patent, titled 'Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder (SUD),' strengthens the company's intellectual property portfolio.
DIFS™ is a non-invasive, drug-free treatment designed to help individuals with various substance use disorders, including opioid, alcohol, and stimulant addictions. The technology works by applying deep-brain stimulation at dynamic frequencies to regulate neural pathways associated with addiction and withdrawal symptoms.
The technology aims to address chronic relapse by targeting underlying anxiety, depression, and cravings through neuromodulation, potentially offering an alternative to traditional treatments like medication-assisted therapy (MAT) that may have accessibility issues and side effects.
Nexalin Technology (Nasdaq: NXL) ha ricevuto l'approvazione del brevetto USPTO per la sua tecnologia di Stimolazione a Frequenza Intracranica Profonda (DIFS™), specificamente per il trattamento dei Disturbi da Uso di Sostanze (SUD). Il brevetto, intitolato 'Metodo di Stimolazione a Frequenza Dinamica a Corrente Alternata per il Disturbo da Uso di Oppioidi (OUD) e Disturbo da Uso di Sostanze (SUD)', rafforza il portafoglio di proprietà intellettuale dell'azienda.
DIFS™ è un trattamento non invasivo e privo di farmaci progettato per aiutare gli individui con vari disturbi da uso di sostanze, comprese le dipendenze da oppioidi, alcol e stimolanti. La tecnologia funziona applicando stimolazione cerebrale profonda a frequenze dinamiche per regolare i percorsi neurali associati alla dipendenza e ai sintomi di astinenza.
La tecnologia mira a affrontare le ricadute croniche mirando a ansia, depressione e desideri sottostanti attraverso la neuromodulazione, offrendo potenzialmente un'alternativa ai trattamenti tradizionali come la terapia assistita da farmaci (MAT) che possono presentare problemi di accessibilità ed effetti collaterali.
Nexalin Technology (Nasdaq: NXL) ha recibido la aprobación de patente USPTO para su tecnología de Estimulación de Frecuencia Intracraneal Profunda (DIFS™), específicamente para el tratamiento de los Trastornos por Uso de Sustancias (SUD). La patente, titulada 'Método de Estimulación de Frecuencia Dinámica de Corriente Alterna para el Trastorno por Uso de Opioides (OUD) y Trastorno por Uso de Sustancias (SUD)', refuerza el portafolio de propiedad intelectual de la empresa.
DIFS™ es un tratamiento no invasivo y libre de medicamentos diseñado para ayudar a las personas con varios trastornos por uso de sustancias, incluidas las adicciones a opioides, alcohol y estimulantes. La tecnología funciona aplicando estimulación cerebral profunda a frecuencias dinámicas para regular las vías neuronales asociadas con la adicción y los síntomas de abstinencia.
La tecnología tiene como objetivo abordar las recaídas crónicas al dirigirse a la ansiedad, la depresión y los antojos subyacentes a través de la neuromodulación, ofreciendo potencialmente una alternativa a los tratamientos tradicionales como la terapia asistida por medicamentos (MAT) que pueden tener problemas de accesibilidad y efectos secundarios.
넥살린 테크놀로지 (Nasdaq: NXL)는 물질 사용 장애(SUD) 치료를 위한 심층 두개내 주파수 자극(DIFS™) 기술에 대한 USPTO 특허 승인을 받았습니다. '오피오이드 사용 장애(OUD) 및 물질 사용 장애(SUD)를 위한 교류 동적 주파수 자극 방법'이라는 제목의 이 특허는 회사의 지적 재산 포트폴리오를 강화합니다.
DIFS™는 비침습적이고 약물에 의존하지 않는 치료법으로, 오피오이드, 알코올 및 자극제 중독을 포함한 다양한 물질 사용 장애가 있는 개인을 돕기 위해 설계되었습니다. 이 기술은 중독 및 금단 증상과 관련된 신경 경로를 조절하기 위해 동적 주파수에서 심부 뇌 자극을 적용합니다.
이 기술은 불안, 우울증 및 갈망과 같은 근본적인 문제를 겨냥하여 만성 재발을 해결하는 것을 목표로 하며, 접근성 문제와 부작용이 있을 수 있는 약물 보조 치료(MAT)와 같은 전통적인 치료법에 대한 대안을 제공할 수 있습니다.
Nexalin Technology (Nasdaq: NXL) a reçu l'approbation de brevet USPTO pour sa technologie de Stimulation de Fréquence Intracrânienne Profonde (DIFS™), spécifiquement pour le traitement des Troubles de l'Usage de Substances (SUD). Le brevet, intitulé 'Méthode de Stimulation de Fréquence Dynamique à Courant Alterné pour le Trouble de l'Usage d'Opioïdes (OUD) et le Trouble de l'Usage de Substances (SUD)', renforce le portefeuille de propriété intellectuelle de l'entreprise.
DIFS™ est un traitement non invasif et sans médicament conçu pour aider les individus souffrant de divers troubles liés à l'usage de substances, y compris les dépendances aux opioïdes, à l'alcool et aux stimulants. La technologie fonctionne en appliquant une stimulation cérébrale profonde à des fréquences dynamiques pour réguler les voies neuronales associées à la dépendance et aux symptômes de sevrage.
La technologie vise à traiter les rechutes chroniques en ciblant l'anxiété, la dépression et les envies sous-jacentes par le biais de la neuromodulation, offrant potentiellement une alternative aux traitements traditionnels comme la thérapie assistée par médicaments (MAT) qui peuvent présenter des problèmes d'accessibilité et des effets secondaires.
Nexalin Technology (Nasdaq: NXL) hat die Genehmigung des USPTO für seine Technologie der Tiefen Intrakraniellen Frequenzstimulation (DIFS™) erhalten, die speziell zur Behandlung von Substanzgebrauchsstörungen (SUD) entwickelt wurde. Das Patent mit dem Titel 'Wechselstrom-Dynamische Frequenzstimulationsmethode für Opioidgebrauchsstörung (OUD) und Substanzgebrauchsstörung (SUD)' stärkt das geistige Eigentum des Unternehmens.
DIFS™ ist eine nicht-invasive, medikamentenfreie Behandlung, die darauf abzielt, Menschen mit verschiedenen Substanzgebrauchsstörungen, einschließlich Opioid-, Alkohol- und Stimulantensucht, zu helfen. Die Technologie funktioniert, indem sie tiefen Hirnstimulationen bei dynamischen Frequenzen anwendet, um die neuronalen Wege zu regulieren, die mit Sucht und Entzugssymptomen verbunden sind.
Die Technologie zielt darauf ab, chronische Rückfälle anzugehen, indem sie zugrunde liegende Angstzustände, Depressionen und Gelüste durch Neuromodulation anspricht und möglicherweise eine Alternative zu traditionellen Behandlungen wie medikamentengestützter Therapie (MAT) bietet, die möglicherweise Zugangsprobleme und Nebenwirkungen aufweisen.
- Secured USPTO patent approval for DIFS™ technology, strengthening intellectual property portfolio
- Technology addresses large market opportunity in worldwide substance use disorders
- Offers non-invasive, drug-free alternative to traditional addiction treatments
- Technology's efficacy and market adoption remain unproven
- Faces competition from established treatment methods like medication-assisted therapy (MAT)
Insights
Nexalin's newly secured USPTO patent for their Deep Intracranial Frequency Stimulation (DIFS™) technology represents a significant intellectual property milestone in the addiction treatment space. This patent specifically covers alternating current dynamic frequency stimulation for treating substance use disorders, including opioid, alcohol, and stimulant dependencies.
The technology's core value proposition lies in its non-invasive, drug-free approach to neuromodulation, potentially addressing a critical gap in the current treatment landscape. While conventional addiction treatments like medication-assisted therapy (MAT) face challenges with accessibility, pharmaceutical dependency, and side effects, Nexalin's approach targets the neurological pathways associated with addiction through non-invasive means.
What makes this patent particularly valuable is its application to multiple substance use disorders rather than a single addiction type. By targeting underlying anxiety, depression, and cravings that drive relapse, the technology adopts a more holistic approach to addiction treatment. However, it's important to note that while the patent secures their intellectual property rights, the pathway to clinical implementation will require demonstration of efficacy through rigorous clinical studies and regulatory approval.
This patent strengthens Nexalin's position as they develop their neuromodulation platform, but commercial success will ultimately depend on clinical validation, regulatory clearance, healthcare provider adoption, and reimbursement pathways—all significant hurdles in bringing new medical technologies to market in the mental health and addiction space.
This patent grant marks a material enhancement to Nexalin's intellectual property portfolio, providing crucial protection for their core DIFS™ technology in the specific application of substance use disorders. For a
The strategic value of this patent lies in its application targeting substance use disorders—a persistent public health challenge with significant unmet needs. By securing exclusive rights to this application of their technology, Nexalin positions itself favorably in a competitive landscape where non-pharmaceutical approaches to addiction treatment are increasingly sought after.
From an investment perspective, this patent represents a critical intangible asset that strengthens Nexalin's competitive moat. Without patent protection, the company's ability to commercialize its technology would be significantly compromised. While the patent itself doesn't generate immediate revenue, it creates essential protection for future commercialization efforts and potential licensing opportunities.
For a nascent medical technology company like Nexalin, building a robust IP portfolio is a key milestone in their development pathway and validates their R&D investments. The patent doesn't eliminate execution risk or guarantee market success, but it removes a significant uncertainty factor by securing their proprietary position in treating substance use disorders with their DIFS™ technology—potentially creating long-term shareholder value if the technology achieves clinical and commercial success.
Patent Approval Reinforces Nexalin’s Leadership in Non-Invasive Brain Stimulation for Addiction Treatment
HOUSTON, TX, April 14, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is pleased to announce that the United States Patent and Trademark Office (USPTO) has officially granted its patent titled "Alternating Current Dynamic Frequency Stimulation Method for Opioid Use Disorder (OUD) and Substance Use Disorder (SUD)."
This milestone further strengthens Nexalin’s intellectual property portfolio and affirms the potential of its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology, a non-invasive and drug-free solution designed to aid individuals struggling with substance use disorders (SUDs), including opioid use disorder (OUD), alcohol use disorder (AUD), and stimulant addiction such as cocaine and methamphetamine dependence. By applying non-invasive deep-brain stimulation at dynamic frequencies, DIFS™ technology may help regulate neural pathways linked to addiction and withdrawal symptoms, offering an alternative treatment pathway for individuals seeking recovery.
Mark White, CEO of Nexalin Technology, remarked, “Securing this patent grant from the USPTO is a significant achievement for Nexalin as we continue to push the boundaries of non-invasive brain stimulation. Substance use disorders remain one of the greatest public health challenges worldwide, and our DIFS™ technology has the potential to introduce a transformative approach to treatment. With this official patent in place, we are further cementing our role as pioneers in the field of addiction and mental health therapy with a safe and effective brain-based treatment. Chronic relapse among individuals with substance use disorders is often driven by underlying anxiety, depression, and persistent cravings. Our DIFS™ technology is designed to address these core symptoms through targeted neuromodulation. By potentially alleviating anxiety and depression, DIFS™ may also reduce the cravings that lead to relapse—offering a promising pathway to improved treatment outcomes and long-term recovery.”
Millions of individuals worldwide are affected by substance use disorders, including opioid dependency, alcoholism, and stimulant abuse. While traditional treatment methods such as medication-assisted therapy (MAT) and behavioral interventions exist, they come with accessibility issues, pharmaceutical dependency, and potential side effects. Nexalin’s DIFS™ technology represents a forward-thinking alternative, aiming to ease withdrawal symptoms and support long-term recovery without the risks associated with conventional therapies.
David Owens, CMO of Nexalin Technology, added, “Addressing the addiction crisis requires new, effective, and non-invasive treatment options. The official granting of this patent confirms the innovative nature of our DIFS™ technology and underscores its potential impact on addiction treatment. Nexalin remains dedicated to advancing non-invasive solutions that meet pressing medical needs, and this patent approval marks another step in our mission to redefine care standards in addiction and mental health treatment.”
This patent joins Nexalin’s expanding intellectual property portfolio, which includes groundbreaking developments in non-invasive neuromodulation for addiction, mental health, and neurological disorders. As the Company continues to refine its innovative treatment solutions, Nexalin remains committed to delivering breakthrough technologies that improve patient care and transform recovery strategies.
For more information about Nexalin Technology and its innovative medical technology solutions, visit www.nexalin-usa.com.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.
Forward-looking statement
This press release contains statements that constitute “forward-looking statements,” These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2023, and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC’s website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Contact:
Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com
FAQ
What is the new patent granted to Nexalin Technology (NXL) for substance use disorder treatment?
How does Nexalin's DIFS™ technology work for addiction treatment?
What types of substance use disorders can Nexalin's DIFS™ technology treat?
What advantages does Nexalin's DIFS™ technology offer over traditional addiction treatments?
